2023 CORPORATE RESPONSIBILITY REPORT - Biogen

1 2023. CORPORATE . RESPONSIBILITY . REPORT . OVERVIEW ACCESS & HEALTH EQUITY WORKFORCE COMMUNITY IMPACT ENVIRONMENT REPORTING 2. Published May 2024. Table of contents 3 OVERVIEW 44 COMMUNITY IMPACT. 4 CEO letter 45 Executive summary 6 2023 highlights 46 Our values in action 7 Growing our purpose-driven organization 46 Advancing health equity and improving 8 Advancing an ethical culture health outcomes 9 Promoting responsible operations 49 STORY Prescribing food, revolutionizing 3. 11 Promoting diversity, equity and inclusion health: The transformative impact of food 13 Engaging diverse stakeholders as medicine 52 SPOTLIGHT Activating employees 14 ACCESS & HEALTH EQUITY 14. 15 Executive summary 53 ENVIRONMENT. 16 STORY Working to drive trust for 54 Executive summary patients: Connecting diverse communities 55 STORY Solothurn site champions to clinical research sustainability 17 Bolstering the clinical research 56 Our strategy and approach to ecosystem cross-cutting issues 21 Ensuring access to healthcare 58 Responsible product development and medicines 61 Sustainable operations 24 SPOTLIGHT Worldwide Patient Access 62 Engaged suppliers & Reimbursement for Spinraza 25 Engaging and collaborating with 29.

2 The community 63 REPORTING. 44. 27 Navigating the unique patient journey 64 About this REPORT 66 ESG data table 72 SASB index 29 WORKFORCE 76 Task Force on Climate-related Financial 30 Executive summary Disclosures (TCFD) Statement 31 STORY Enhancing employee wellness 79 GRI content index through a holistic health approach 83 Safe harbor 32 Fostering a culture of well-being and engagement 38 Supporting growth and opportunity 40 Advancing diversity, equity and inclusion 41 SPOTLIGHT Employee Resource Groups 43 STORY Being your authentic self at work: 53. Kali's story 63. Biogen 2023 CORPORATE RESPONSIBILITY REPORT . OVERVIEW ACCESS & HEALTH EQUITY WORKFORCE COMMUNITY IMPACT ENVIRONMENT REPORTING 3. OVERVIEW. Key awards #33 on 2024 Just Capital's JUST 100. Named to the 2023 Dow Jones Sustainability World Index for 11th time, receiving the distinction of Top 1% S&P Global CORPORATE Sustainability Assessment Scores 100% on the Human Rights Campaign's 2023 Best Place to Work for LGBTQ+ Equality for the 10th year in a row 100% on the Disability Equality Index's 2023 Best Places to Work for Disability Inclusion for 6th year in a row Elizabeth lives with Friedreich ataxia.

3 Watch her story on Biogen 2023 CORPORATE RESPONSIBILITY REPORT . OVERVIEW ACCESS & HEALTH EQUITY WORKFORCE COMMUNITY IMPACT ENVIRONMENT REPORTING 4. CEO letter As we reflect on the past year and set our sights the for patients, ages 16 and older, on the path ahead, I am truly inspired by the with Friedreich ataxia. In the , more than progress we have made to advance Biogen 's 1,000 patients were using the therapy as of enduring legacy of pioneering innovative mid-February, representing nearly 25% of the science to deliver medicines that transform eligible population, and we are working toward patients' lives and create enduring value for expanding access to even more people for this our communities and our shareholders. Our groundbreaking treatment. We also entered mission and business strategy are grounded in new markets with SPINRAZA (nusinersen), our commitment to responsible business, and which is now available in 70 countries, including in 2023, we refined our CORPORATE RESPONSIBILITY 21 classified as low- to middle-income.

4 Strategy to advance our evolving business priorities and align with areas where we believe In April 2023, we received accelerated approval we can have the greatest impact. from the Food and Drug Administration (FDA) for QALSODY (tofersen) for the treatment Our commitment to of adults with amyotrophic lateral sclerosis access and health equity (ALS), associated with a mutation in the Patients are at the heart of everything we do, superoxide dismutase 1 (SOD1) gene, making it and they inspire our unwavering commitment to the first approved treatment to target a genetic excellence. Across the company, we continue cause of ALS. This approval for a disease that to take meaningful action to advance equitable affects an estimated 2,876 people worldwide access to quality healthcare and medicines. reflected our core tenant of keeping patients To advance that vision from our pipeline to our at the forefront.

5 We attained this milestone commercialization strategies and beyond, we through the decades-long tenacity, determination intend to focus on four key pillars: ensuring and the profound commitment from the Biogen access to healthcare and medicines, navigating team to help people living with ALS. With the I am truly inspired by the progress we have made the unique patient journey, bolstering the Early Access Programs and subsequent market to advance Biogen 's enduring legacy of pioneering clinical research ecosystem, and engaging and approvals, approximately 470 patients are using innovative science to deliver medicines that transform collaborating with the community. this treatment as of December 2023. patients' lives and create enduring value for our In 2023, we advanced our pipeline of potential We recognize health outcomes often depend communities and our shareholders.

6 Novel therapies and our goal of increasing on factors beyond the control of patients and . representation of diverse populations in our their providers, such as disparities across age, Christopher A. Viehbacher clinical trials. We added four first-in-class gender, race, ethnicity, geographic locations President and Chief Executive Officer medicines to our portfolio, the second globally and socioeconomic level. By increasing most in the industry last year. In addition, participation of underrepresented populations SKYCLARYS (omaveloxolone) recently became in clinical trials, as we have done in Alzheimer's the first treatment approved in the and disease and lupus, we believe we can better Biogen 2023 CORPORATE RESPONSIBILITY REPORT . OVERVIEW ACCESS & HEALTH EQUITY WORKFORCE COMMUNITY IMPACT ENVIRONMENT REPORTING 5. CEO letter serve patients of many different profiles.

7 In By staying true This diversity is also modeled by our Board Our employees recognize the link between human 2023, 89% of clinical trials delivered race and to our values of Directors and our leadership team. As of and environmental health, and we remain active in ethnicity enrollment targets that reflect the April 2024, 62% of non-employees on our Board our sustainability efforts. By improving efficiency and embracing epidemiology of the disease. In the last year, we self-identify as women and/or ethnic or racial and reducing waste, as well as water and energy also bolstered our overall health equity efforts, our mission minorities while of those VP and above consumption, we are working to reduce costs and working to embed it into the early research and with passion, at Biogen are women. Last year, on behalf of environmental impacts, including in our labs.

8 In drug development process. we believe we Biogen , I received the Latino CORPORATE Directors 2023, we became the first large biotech to get will continue to Association's CORPORATE Visionary Award. It was 100% of our labs certified through My Green Lab, Evolving our culture make a positive an honor to celebrate that distinction, while also a program recognized by the United Nations' Race Adapting our business and the way we operate recognizing the progress we have made toward a to Zero campaign for setting the standard for best are essential for us to thrive in a rapidly impact on the more diverse and inclusive workplace. practices in laboratory sustainability. evolving healthcare landscape. In 2023, we lives of patients embarked on a new operating model with and communities Making meaningful contributions Progress seldom happens in isolation, so I also increased accountability and empowering worldwide.

9 That to communities would like to thank the countless people and our teams to be closer to our customers. Looking beyond our current workforce, we institutions who collaborate on the important work is the future We have embraced change and a renewed see a need to strengthen and diversify the covered in this REPORT : our partners and suppliers, focus on innovation to drive sustainable we are working talent pipeline throughout our industry and patients and patient advocates, thousands success. Employees drive our progress and to create, and we are taking steps to help build it. In 2023, of clinical trial participants and their families, our strong culture, and we are committed I hope the work we refreshed our Community Lab, our flagship caregivers and medical professionals, community to maintaining our spirit of innovation and reflected in this science education program, which has reached leaders and many others.

10 Patient-centricity while advancing a more more than 64,000 students since 2002. Under entrepreneurial business mindset and REPORT inspires the new CoLab name, we are expanding the By staying true to our values and embracing our results-driven approach. One of the key you to play an program's reach, those we expect to serve, as mission with passion, we believe we will continue takeaways from our 2023 internal survey is even greater well as partnerships in our local communities. to make a positive impact on the lives of patients that 81% of employees are driven by and part in it. and communities worldwide. That is the future we believe in Biogen 's purpose. We intend to Through the Biogen Foundation, we helped are working to create, and I hope the work reflected continue harnessing that passion. address social determinants of health, such as in this REPORT inspires you to play an even greater food security and access to healthcare, investing part in it.